This page shows the latest Advate news and features for those working in and with pharma, biotech and healthcare.
The web-based myPKFiT supports the pharma firm's Advate treatment. US regulators have approved Shire’s new web-based dosing software for its recombinant Factor VIII haemophilia A treatment Advate. ... A version of the myPKFiT for Advate software has
The European Commission has approved Shire’s haemophilia A therapy Adynovi, a new long-acting version of its long-established Advate product.
The injectable is a new form of Advate - a haemophilia A treatment Shire acquired from Baxalta in a $32bn takeover - and offers twice-weekly prophylactic use as well as on-demand
to wrest market share from established haemophilia A therapies such as Shire/Baxalta's Advate (octocog alfa).
The merger will couple Baxalta's haemophilia franchise - including its big selling Advate product for haemophilia A and long-acting follow-up BAX-855 which is nearing the market- with Shire
Last month it secured FDA approval for long-acting haemophilia A therapy Adynovate (formerly BAX 855), a follow-up to its big-selling Advate brand.
More from news
Approximately 3 fully matching, plus 21 partially matching documents found.
No results were found
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...